Cormay Group: Hematology Analyzers for Confident and Efficient Patient Diagnosis
Flavio Finotello, CCO
In the field of in-vitro diagnostics, clinicians and physicians demand accurate test results so that patients can commence treatment as early as possible with the confidence of a positive health outcome. The Cormay Group, headquartered in Poland, develops in-vitro diagnostic solutions that combine innovative analyzers with high-performance reagents to significantly reduce false readings in both clinical chemistry and hematology. “Our driving principle is to protect life, our most valuable asset,” Flavio Finotello, CCO of Cormay. “With over 35 years of experience and know-how, our team of R&D experts constantly strive to develop new ways to enhance the quality of diagnostic test results through the combination of unique reagent formulations with multi-patented analyzer technology.” The Cormay Group comprises two companies—Swiss-based Orphee dedicated to hematology, and Polish origin Cormay specialized in clinical chemistry.
“Unlike our competitors, we utilize our expertise in the production of reagents and analyzers to bring the sophistication and the intelligence demanded by the world’s largest clinical laboratories to small and medium-sized labs,” mentions Finotello. Orphee recently expanded its highly acclaimed Mythic hematology analyzer portfolio with the launch of the new Mythic 60. Comprising seven patents, including LED-based flow cytometry single-cell measurement technology, the new Mythic analyzer ensures accurate diagnosis by providing true 5-diff separation.
The Mythic analyzer’s ability to accurately characterize each of the five white blood cell groupings is crucial to avoiding misdiagnosis. Mythic’s multi-patented technology achieves full separation of white blood cells by performing measurements on native blood cells whilst maintaining the integrity of each cell throughout the measurement process. When combined with a proprietary dynamic clustering algorithm that compensates for subtle differences in white blood cell populations from patient to patient, Mythic analyzers are able to deliver faster and more reliable results.
With over 35 years of experience and know-how, our team of R&D experts constantly strive to develop new ways to enhance the quality of diagnostic test results
Mythic has primarily been a boon to clients situated in locations around the world where blood samples taken from patients can experience unpredictable delays and prolonged exposure to higher temperatures during transportation to the clinical laboratory.“The combination of our analyzers’ single-cell measurements, full separation of the white blood cell types, and dynamic clustering help clients to create the purest of scattergrams for diagnostic test results you can trust,” adds Finotello. “Our innovative analyzers immediately benefit the clinical labs through a significant decrease in false readings.”
Similarly, when it comes to clinical chemistry, Cormay’s recently launched Accent analyzers consist of patented concave grating light splitting technology, which delivers enhanced sensitivity, highest signal to performance, and low stray light to provide reliable diagnostic results for the correct treatment process.
The Cormay Group’s emphasis on quality reagents and innovative technologies also removes one of the biggest hurdles, the high costs related to reagent consumption. To help clinical laboratories generate significant savings, the company’s multi-patented analyzer technologies combined with a comprehensive portfolio of reagents offering the longest onboard and calibration stabilities in the market, more time can be spent analyzing and measuring patient samples and less on recalibration and controls. Clinical laboratories can then reinvest these significant savings to enhance their infrastructure by adding new skills that improve the standard of in-patient service performance.
Moving forward, the Cormay Group is planning to expand its scope across other IVD segments, such as immunology, coagulology, and urinalysis. “We are constantly looking to expand through acquisitions of companies having an in-vitro diagnostics portfolio,” concludes Finotello.